Lillsunde Katja-Emilia, Tomašič Tihomir, Kikelj Danijel, Tammela Päivi
Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
Chem Biol Drug Des. 2017 Dec;90(6):1147-1154. doi: 10.1111/cbdd.13034. Epub 2017 Jul 3.
Marine organisms and their metabolites are a diverse source of scaffolds for potential pharmacological molecular probes and, less frequently, for pharmaceutical lead compounds. In this study, 157 synthetic analogues of marine sponge-derived alkaloids clathrodin and oroidin were screened against replicon models of two RNA viruses, hepatitis C (HCV) and Chikungunya virus (CHIKV) as part of a larger screening project. Four compounds were found to selectively inhibit the HCV replicon (IC 1.6-4.6 μm). These belong to the 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole class of compounds originally designed to target the ATP-binding site of bacterial DNA gyrase. The ATP-binding site of this bacterial protein has high structural similarity to the ATP-binding site of heat-shock protein 90 (Hsp90), a host cell chaperone universally required for viral replication, which led us to examine inhibition of Hsp90 as the compounds' potential mechanism of action. Binding of the four hit compounds to Hsp90 was evaluated through microscale thermophoresis and molecular modeling, which supported our hypothesis of interaction with Hsp90 (K 18-79 μm) as basis for the compounds' antiviral activity. The presented novel structural class of small molecules that target the Hsp90 ATP-binding site has excellent potential for further antiviral drug development because of the compounds' low toxicity and synthetic accessibility.
海洋生物及其代谢产物是潜在药理分子探针支架的多样化来源,而作为药物先导化合物的来源则相对较少。在本研究中,作为一个更大规模筛选项目的一部分,对157种海绵来源的生物碱克拉索丁和奥罗丁的合成类似物针对两种RNA病毒(丙型肝炎病毒(HCV)和基孔肯雅病毒(CHIKV))的复制子模型进行了筛选。发现四种化合物能选择性抑制HCV复制子(IC 1.6 - 4.6μm)。这些化合物属于4,5,6,7 - 四氢苯并[1,2 - d]噻唑类化合物,最初设计用于靶向细菌DNA促旋酶的ATP结合位点。这种细菌蛋白的ATP结合位点与热休克蛋白90(Hsp90)的ATP结合位点具有高度结构相似性,热休克蛋白90是病毒复制普遍需要的宿主细胞伴侣蛋白,这促使我们研究抑制Hsp90作为这些化合物潜在的作用机制。通过微量热泳和分子建模评估了这四种命中化合物与Hsp90的结合,这支持了我们关于与Hsp90相互作用(K 18 - 79μm)作为化合物抗病毒活性基础的假设。由于这些化合物毒性低且易于合成,所呈现的靶向Hsp90 ATP结合位点的新型小分子结构类具有进一步开发抗病毒药物的巨大潜力。